The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial
Annals of Oncology, 08/08/2012
Huijbers A et al. – This study confirms the intra-tumor stroma ratio as a prognostic factor. This parameter could be a valuable and low cost addition to the TNM status and next to current high-risk parameters such as microsatellite instability status used in routine pathology reporting. When adding the stroma-parameter to the ASCO criteria, the rate of ‘undertreated’ patients dropped from 5.9% to 4.3%, the ‘overtreated’ increased with 6.8% but the correctly classified increased with an additional 14%.
Methods- Tissue samples from the most invasive part of the primary tumor of 710 patients (52% Stage II, 48% Stage III) participating in the VICTOR trial were analyzed for their tumor-stroma percentage.
- Stroma-high (>50%) and stroma-low (?50%) groups were evaluated with respect to survival times.
- Overall and disease-free survival times (OS and DFS) were significantly lower in the stroma-high group (OS P < 0.0001, hazard ratio (HR) = 1.96; DFS P < 0.0001, HR = 2.15).
- The 5-year OS was 69.0% versus 83.4% and DFS 58.6% versus 77.3% for stroma-high versus stroma-low patients.
